GHRP-2 Attenuates Inflammation in Human Ovarian Granulosa Cells via p38, JNK, and NF-κB Pathways
Background
During ovulation, inflammatory processes are critical, involving mediators like cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8). Dysregulation of this inflammatory cascade can impact ovarian function and fertility. Ghrelin, a gut hormone, is known to modulate inflammatory signaling through its receptor, the growth hormone secretagogue receptor (GHSR). While ghrelin's systemic roles are well-studied, its specific local effects within ovarian tissue, particularly its ability to counteract pro-inflammatory signals, remain less clear. This study investigates whether ghrelin signaling, mimicked by its synthetic analog GHRP-2, can serve an anti-inflammatory role in the specific context of protein kinase C (PKC)-mediated inflammation in human ovarian granulosa cells, a key cell type in follicle development and ovulation.
Study Design
This in vitro study used the KGN human ovarian granulosa cell line to model ovarian inflammation. Inflammation was induced using phorbol 12, 13-didecanoate (PDD), a potent activator of protein kinase C (PKC). The cells were then treated with the synthetic ghrelin analog GHRP-2. Researchers measured the expression of COX-2 and IL-8 at both the protein and mRNA levels. They also assessed the promoter activity of these genes and measured the secretion of downstream inflammatory molecules prostaglandin E2 (PGE₂) and IL-8 into the cell culture media. The study also investigated the specific signaling pathways involved, using inhibitors for MKP-1 and PP2A to clarify the mechanism of GHRP-2's action.
Results
GHRP-2 demonstrated significant anti-inflammatory effects against PDD-induced inflammation. It attenuated the expression of both protein and mRNA for COX-2 and IL-8, and also reduced the promoter activity of their respective genes. Consequently, the secretion of prostaglandin E2 (PGE₂) and IL-8 was suppressed. GHRP-2 was also found to promote the degradation of COX-2 and IL-8 proteins through both proteasomal and lysosomal pathways. Mechanistically, PDD was found to induce COX-2 via the p38, JNK, ERK, and NF-κB pathways, while inducing IL-8 via p38, JNK, and ERK.
GHRP-2 specifically counteracted these effects by reducing the PDD-induced phosphorylation of
p38andJNK, decreasingAP-1reporter activation, and inhibitingNF-κBnuclear translocation and its subsequent reporter activation. The study pinpointed the involvement ofMKP-1andPP2Aphosphatases, as inhibiting them reduced GHRP-2's suppressive effects onCOX-2andIL-8expression.
Key Findings
- GHRP-2 attenuated PDD-induced expression of protein, mRNA, and promoter activity for both COX-2 and IL-8 genes.
- GHRP-2 reduced the secretion of prostaglandin E2 (PGE₂) and IL-8 from inflamed granulosa cells.
- The peptide inhibited the PDD-induced phosphorylation of p38 and JNK signaling proteins.
- GHRP-2 suppressed PDD-induced NF-κB nuclear translocation and activation.
- Inhibitors of MKP-1 and PP2A diminished the anti-inflammatory effects of GHRP-2 on COX-2 and IL-8 expression.
Why It Matters
This research provides a cellular mechanism for ghrelin analogs like GHRP-2 exerting anti-inflammatory effects within the ovary. For biohackers or clinicians interested in female reproductive health, this suggests a potential role for ghrelin system agonists in managing conditions characterized by ovarian inflammation. The findings imply that modulating ghrelin signaling could be a therapeutic strategy to control local inflammatory responses during the ovulatory cycle. This is an early, in vitro study, so it is far from a clinical protocol. However, it establishes a compelling rationale for further investigation into ghrelin-based peptides for gynecological inflammatory conditions. It also suggests that the timing of GHRP-2 administration relative to ovulatory triggers could be a relevant factor to explore in future research aiming to optimize ovarian function.
